Fig. 5

BCAS1-positive oligodendrocytes contribute to remyelination of ODS lesions. a Relative MAG mRNA expression in the lesion center at different time points compared to controls. Expression levels are normalized to the mean number of Olig2+ cells at this time point. b Quantification of BCAS1 +/MAG+ actively myelinating oligodendrocytes at different time points after lesion initiation. White bars = lesion, grey bars = perilesion, light grey bar = controls. c Quantification of BCAS1+ (left bar) and BCAS1+/MAG+ (right bar) oligodendrocytes with and without BrdU immunoreactivity at different time points inside the lesion. Black bars = BrdU+ cells, white bars = BrdU⁻ cells. d, e BCAS1/MAG/BrdU immunofluorescence triple labeling in an ODS lesion at 14 dpc. Depicted are an actively myelinating BCAS1+/MAG+ oligodendrocyte without BrdU labeling (d) and a BCAS1 +/MAG⁻ oligodendrocyte with nuclear BrdU labeling and dysfunctional morphology (e) (BrdU = white, BCAS1 = red, MAG = green, DAPI = blue, magnification × 400, scale bar 10 µm). f Olig2/TUNEL double-positive cells, indicating apoptotic oligodendrocytes. g Light microscopic BCAS1/BrdU double labeling depicting a double positive cell with typical apoptotic nuclear morphology. BCAS1 = blue, BrdU = brown, magnification × 400, scale bar 10 µm. If not stated otherwise, one dot = one animal; one-way ANOVA and Tukey’s multiple comparison; mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001)